MovDisordV3, PascalFrancis, Corpus, bibRecord, 002717

Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome

Identifieur interne : 002717 ( PascalFrancis/Corpus ); précédent : 002716; suivant : 002718

Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome

Auteurs : Willibald Gerschlager ; Peter Brown

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0370603

Descripteurs français

Pascal (Inist)
- Homme raide syndrome, Immunoglobuline, Voie intraveineuse, Chimiothérapie, Qualité vie, Etude cas, Traitement, Pronostic, Evolution, Adulte, Mâle, Femelle.

English descriptors

KwdEn :
- Adult, Case study, Chemotherapy, Evolution, Female, Immunoglobulins, Intravenous administration, Male, Prognosis, Quality of life, Stiff man syndrome, Treatment.

Abstract

The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy-vitality with treatment The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome`
A11	`01`	`1`		`@1 GERSCHLAGER (Willibald)`
A11	`02`	`1`		`@1 BROWN (Peter)`
A14	`01`			`@1 Institute of Neurology, Sobell Department of Neurophysiology, Queen Square @2 London @3 GBR @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 National Hospital for Neurology and Neurosurgery, Queen Square @2 London @3 GBR @Z 2 aut.`
A20				`@1 590-593`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000108224770250`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 02-0370603`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy-vitality with treatment The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS.
C02	`01`	`X`		`@0 002B27D01`
C03	`01`	`X`	`FRE`	`@0 Homme raide syndrome @5 01`
C03	`01`	`X`	`ENG`	`@0 Stiff man syndrome @5 01`
C03	`01`	`X`	`SPA`	`@0 Hombre rígido síndrome @5 01`
C03	`02`	`X`	`FRE`	`@0 Immunoglobuline @5 04`
C03	`02`	`X`	`ENG`	`@0 Immunoglobulins @5 04`
C03	`02`	`X`	`SPA`	`@0 Inmunoglobulina @5 04`
C03	`03`	`X`	`FRE`	`@0 Voie intraveineuse @5 05`
C03	`03`	`X`	`ENG`	`@0 Intravenous administration @5 05`
C03	`03`	`X`	`SPA`	`@0 Vía intravenosa @5 05`
C03	`04`	`X`	`FRE`	`@0 Chimiothérapie @5 06`
C03	`04`	`X`	`ENG`	`@0 Chemotherapy @5 06`
C03	`04`	`X`	`SPA`	`@0 Quimioterapia @5 06`
C03	`05`	`X`	`FRE`	`@0 Qualité vie @5 07`
C03	`05`	`X`	`ENG`	`@0 Quality of life @5 07`
C03	`05`	`X`	`SPA`	`@0 Calidad vida @5 07`
C03	`06`	`X`	`FRE`	`@0 Etude cas @5 16`
C03	`06`	`X`	`ENG`	`@0 Case study @5 16`
C03	`06`	`X`	`SPA`	`@0 Estudio caso @5 16`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`08`	`X`	`FRE`	`@0 Pronostic @5 18`
C03	`08`	`X`	`ENG`	`@0 Prognosis @5 18`
C03	`08`	`X`	`SPA`	`@0 Pronóstico @5 18`
C03	`09`	`X`	`FRE`	`@0 Evolution @5 19`
C03	`09`	`X`	`ENG`	`@0 Evolution @5 19`
C03	`09`	`X`	`SPA`	`@0 Evolución @5 19`
C03	`10`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`10`	`X`	`ENG`	`@0 Adult @5 20`
C03	`10`	`X`	`SPA`	`@0 Adulto @5 20`
C03	`11`	`X`	`FRE`	`@0 Mâle @5 21`
C03	`11`	`X`	`ENG`	`@0 Male @5 21`
C03	`11`	`X`	`SPA`	`@0 Macho @5 21`
C03	`12`	`X`	`FRE`	`@0 Femelle @5 22`
C03	`12`	`X`	`ENG`	`@0 Female @5 22`
C03	`12`	`X`	`SPA`	`@0 Hembra @5 22`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Muscle strié pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Striated muscle disease @5 37`
C07	`02`	`X`	`SPA`	`@0 Músculo estriado patología @5 37`
N21				`@1 203`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0370603 INIST
ET :	Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome
AU :	GERSCHLAGER (Willibald); BROWN (Peter)
AF :	Institute of Neurology, Sobell Department of Neurophysiology, Queen Square/London/Royaume-Uni (1 aut., 2 aut.); National Hospital for Neurology and Neurosurgery, Queen Square/London/Royaume-Uni (2 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 3; Pp. 590-593; Bibl. 23 ref.
LA :	Anglais
EA :	The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy-vitality with treatment The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS.
CC :	002B27D01
FD :	Homme raide syndrome; Immunoglobuline; Voie intraveineuse; Chimiothérapie; Qualité vie; Etude cas; Traitement; Pronostic; Evolution; Adulte; Mâle; Femelle
FG :	Homme; Muscle strié pathologie
ED :	Stiff man syndrome; Immunoglobulins; Intravenous administration; Chemotherapy; Quality of life; Case study; Treatment; Prognosis; Evolution; Adult; Male; Female
EG :	Human; Striated muscle disease
SD :	Hombre rígido síndrome; Inmunoglobulina; Vía intravenosa; Quimioterapia; Calidad vida; Estudio caso; Tratamiento; Pronóstico; Evolución; Adulto; Macho; Hembra
LO :	INIST-20953.354000108224770250
ID :	02-0370603

Links to Exploration step

Pascal:02-0370603

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome</title>
<author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0370603</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0370603 INIST</idno>
<idno type="RBID">Pascal:02-0370603</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002717</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome</title>
<author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Evolution</term>
<term>Female</term>
<term>Immunoglobulins</term>
<term>Intravenous administration</term>
<term>Male</term>
<term>Prognosis</term>
<term>Quality of life</term>
<term>Stiff man syndrome</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme raide syndrome</term>
<term>Immunoglobuline</term>
<term>Voie intraveineuse</term>
<term>Chimiothérapie</term>
<term>Qualité vie</term>
<term>Etude cas</term>
<term>Traitement</term>
<term>Pronostic</term>
<term>Evolution</term>
<term>Adulte</term>
<term>Mâle</term>
<term>Femelle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy-vitality with treatment The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GERSCHLAGER (Willibald)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BROWN (Peter)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>590-593</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000108224770250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0370603</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy-vitality with treatment The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B27D01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme raide syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Stiff man syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre rígido síndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Immunoglobuline</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Immunoglobulins</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inmunoglobulina</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Voie intraveineuse</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Intravenous administration</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vía intravenosa</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Qualité vie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Quality of life</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Calidad vida</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Case study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Evolution</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Evolution</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Evolución</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Mâle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Male</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Macho</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Femelle</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Female</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Hembra</s0>
<s5>22</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Muscle strié pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>37</s5>
</fC07>
<fN21><s1>203</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0370603 INIST</NO>
<ET>Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome</ET>
<AU>GERSCHLAGER (Willibald); BROWN (Peter)</AU>
<AF>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square/London/Royaume-Uni (1 aut., 2 aut.); National Hospital for Neurology and Neurosurgery, Queen Square/London/Royaume-Uni (2 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 3; Pp. 590-593; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy-vitality with treatment The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS.</EA>
<CC>002B27D01</CC>
<FD>Homme raide syndrome; Immunoglobuline; Voie intraveineuse; Chimiothérapie; Qualité vie; Etude cas; Traitement; Pronostic; Evolution; Adulte; Mâle; Femelle</FD>
<FG>Homme; Muscle strié pathologie</FG>
<ED>Stiff man syndrome; Immunoglobulins; Intravenous administration; Chemotherapy; Quality of life; Case study; Treatment; Prognosis; Evolution; Adult; Male; Female</ED>
<EG>Human; Striated muscle disease</EG>
<SD>Hombre rígido síndrome; Inmunoglobulina; Vía intravenosa; Quimioterapia; Calidad vida; Estudio caso; Tratamiento; Pronóstico; Evolución; Adulto; Macho; Hembra</SD>
<LO>INIST-20953.354000108224770250</LO>
<ID>02-0370603</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002717 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002717 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0370603
   |texte=   Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome

Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri